1/27
08:02 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $11.00 price target on the stock, down previously from $56.00.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $11.00 price target on the stock, down previously from $56.00.
1/27
08:02 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $11.00 price target on the stock, down previously from $56.00.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $11.00 price target on the stock, down previously from $56.00.
1/27
06:40 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
1/27
06:40 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
1/27
04:55 am
ntla
Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
Medium
Report
Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
1/27
04:55 am
ntla
Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
Medium
Report
Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
1/14
09:09 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
1/14
09:09 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
1/14
09:09 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
1/13
11:07 am
ntla
Rating for NTLA
Low
Report
Rating for NTLA
1/13
11:07 am
ntla
Rating for NTLA
Low
Report
Rating for NTLA
1/10
08:13 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock, down previously from $14.00.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock, down previously from $14.00.
1/10
08:13 pm
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock, down previously from $14.00.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock, down previously from $14.00.
1/10
09:19 am
ntla
Rating for NTLA
High
Report
Rating for NTLA
1/10
09:19 am
ntla
Rating for NTLA
High
Report
Rating for NTLA
1/10
09:13 am
ntla
Rating for NTLA
High
Report
Rating for NTLA
1/10
09:13 am
ntla
Rating for NTLA
High
Report
Rating for NTLA
11/19
05:25 pm
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
11/18
01:25 pm
ntla
Rating for NTLA
Low
Report
Rating for NTLA
11/18
01:25 pm
ntla
Rating for NTLA
Low
Report
Rating for NTLA
11/18
11:36 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $14.00 price target on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $14.00 price target on the stock.
11/18
11:36 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $14.00 price target on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $14.00 price target on the stock.
11/18
11:34 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at William Blair. They now have a $14.00 price target on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at William Blair. They now have a $14.00 price target on the stock.
11/18
11:34 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at William Blair. They now have a $14.00 price target on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at William Blair. They now have a $14.00 price target on the stock.
11/18
11:20 am
ntla
Rating for NTLA
Low
Report
Rating for NTLA